A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable and Not Eligible for Local Ablation and/or TACE.
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2015
At a glance
- Drugs Sorafenib (Primary) ; Tegafur/uracil (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SADAT
- 04 Aug 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 30 Mar 2012 Trial acronym (SADAT) identified as reported by ClinicalTrials.gov.
- 30 Mar 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.